Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Fed’s Collins says PCE does not change restrictive policy view

Fed’s Collins says PCE does not change restrictive policy view

FXStreetFXStreet2026/08/27 18:36

The Boston Fed President, Suan Collins, crossed the wires on Thursday as the Jackson Hole Symposium began. She said that the recent PCE report does not change the view that policy is restrictive and will lead to gradual disinflation.

Collins added that the jump in US bond yields is “still consistent with price stability,” and added that she has no comment on Bessent’s intervention.

Recently, Collins added via an interview with the Wall Street Journal that a rate hike is warranted if inflation disappoints.

Key highlights:

RECENT PERSONAL CONSUMPTION EXPENDITURES REPORT DID NOT CHANGE MODAL OUTLOOK THAT CURRENT MONETARY POLICY IS RESTRICTIVE AND WILL LEAD TO A GRADUAL DISINFLATION

PORTFOLIO MANAGEMENT FEES HAD AN OUTSIZED INFLUENCE ON HEADLINE INFLATION, WITH MARKET-BASED PRICES MORE IN LINE WITH FED'S TARGET

RECENT INFLATION DATA 'MIXED,' WITH HEADLINE FIGURE STRONGER THAN EXPECTED BUT 'PROMISING SIGNS' IN THE DETAILS

RECENT INCREASE IN BOND YIELDS STILL CONSISTENT WITH PRICE STABILITY, NOT A SIGN INFLATION EXPECTATIONS ARE INCREASING

ABSENT NEW TARIFF AND OIL SHOCKS, THERE ARE REASONS TO THINK INFLATION WILL EASE

SHE IS WATCHING BOND YIELDS, BUT HAS NO COMMENT ON BESSENT'S INTERVENTION

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Electra Therapeutics (ETRA.US) submits US IPO application, leveraging the biotech IPO boom to advance new drug development for immune diseases and cancer.

Electra Therapeutics Inc. has officially filed for an initial public offering (IPO), aiming to leverage the strong IPO performance of the biotechnology sector this year to raise funds for its clinical-stage pipeline of drugs targeting immune-mediated diseases and cancer.

智通财经2026/08/29 03:22
Electra Therapeutics (ETRA.US) submits US IPO application, leveraging the biotech IPO boom to advance new drug development for immune diseases and cancer.